The psychedelic legal landscape is shifting fast
From city-level decriminalization to FDA breakthrough therapy designations, here's what you need to know and where to track the latest changes.
The Current Landscape
Psychedelics like psilocybin, LSD, and MDMA remain Schedule I controlled substances at the federal level in the United States. That classification means they're considered to have no accepted medical use and a high potential for abuse.
But that classification is increasingly at odds with the growing body of clinical research coming out of major academic institutions. State governments, city councils, and federal regulators are all responding in different ways.
What's changing
State-level legalization
Oregon (2020) and Colorado (2022) passed measures creating legal frameworks for psilocybin-assisted therapy.
City decriminalization
Over a dozen U.S. cities have deprioritized enforcement of laws against psychedelics.
FDA designations
Psilocybin and MDMA have received "Breakthrough Therapy" status, fast-tracking clinical trials.
Ketamine access
Already legal and increasingly used off-label for depression. FDA-approved esketamine (Spravato) available since 2019.
Policy trackers we actually trust
Policy shifts by the week. These are the trackers worth bookmarking if you want to stay current.
Psychedelic Alpha
Legalization & Decriminalization Tracker
The most comprehensive, regularly updated interactive map of psychedelic policy reform in the U.S. and beyond. A collaboration with UC Berkeley and Calyx Law.
View the Tracker →Psychedelic Alpha
Worldwide Psychedelic Laws
Global overview of psychedelic legal status by country. Useful if you're researching international retreat options or cross-border travel.
View Worldwide Laws →Where clinical trials stand
Clinical research is the primary pathway toward FDA approval of psychedelic-assisted therapies. Here's the current state of major studies by compound.
- Treatment-resistant depression
- Major depressive disorder
- End-of-life anxiety
- Alcohol use disorder
- Tobacco use disorder
- Post-traumatic stress disorder (PTSD)
- Treatment-resistant depression FDA
- Suicidal ideation
- LSD (anxiety, depression)
- Ibogaine (opioid use disorder)
- 5-MeO-DMT (depression, anxiety)
- Ayahuasca / DMT (depression)
Key organizations in clinical research
The institutions and nonprofits driving the research agenda forward.
MAPS
Multidisciplinary Association for Psychedelic Studies. Leading MDMA-assisted therapy trials for PTSD.
maps.org →Johns Hopkins
Center for Psychedelic & Consciousness Research. Pioneering psilocybin research for depression, addiction, and end-of-life distress.
hopkinspsychedelic.org →UC Berkeley
Center for the Science of Psychedelics. Research, policy analysis, and practitioner training.
psychedelics.berkeley.edu →Imperial College London
Centre for Psychedelic Research. Leading European research institution studying psilocybin and other compounds.
imperial.ac.uk →Usona Institute
Nonprofit research organization. Conducting psilocybin trials for major depressive disorder.
usonainstitute.org →NYU Langone
Center for Psychedelic Medicine. Research on psilocybin for alcohol use disorder and end-of-life distress.
med.nyu.edu →Important notes
The gap between "research is happening" and "this is legal for you" is wide. Three things worth internalizing.
Laws vary by jurisdiction and change frequently. Before pursuing any activities that may carry legal risks, consult with a lawyer in your area. Nothing on this page should be interpreted as permission, endorsement, or guidance to act.
Even with FDA breakthrough therapy status, these substances remain illegal outside of approved research settings until full approval is granted. Participating in a clinical trial and "doing it on your own" are legally and medically very different things.
Oregon's psilocybin services program launched in 2023. Colorado's is in development. These create legal pathways for supervised therapeutic use, but only within those states, only at licensed service centers, and only under specific conditions.
Bookmark these resources
The psychedelic policy landscape is evolving quickly. These sources do the tracking so you don't have to.
Psychedelic Alpha
News, data, and policy updates. The most comprehensive industry tracker.
Visit site →MAPS
Research milestones and advocacy updates from the MDMA-assisted therapy leaders.
Visit site →DoubleBlind
Culture and policy coverage. Longform journalism on the psychedelic movement.
Visit site →